Related Experiment Video

Updated: Mar 30, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Pediatric tuberculosis drug market: an insider perspective on challenges and solutions

I Usherenko1, U Basu Roy2, S Mazlish2

  • 1The Global Alliance for TB Drug Development, New York, New York.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|November 14, 2015
PubMed

Insights

Improving access to pediatric tuberculosis (TB) drugs requires child-friendly formulations and better diagnosis. Incentivizing manufacturers and pooled procurement are key to ensuring supply and affordability for children with TB.

Area of Science:

  • Pediatric pharmacology
  • Global health
  • Infectious disease management

Background:

  • Access to appropriate pediatric tuberculosis (TB) medications remains a significant global challenge.
  • Current TB drug formulations are often unsuitable for children, leading to suboptimal treatment outcomes.
  • Improved diagnosis and reporting systems for pediatric TB are crucial for effective disease control.

Purpose of the Study:

  • To identify key strategies for enhancing access to pediatric tuberculosis drugs.
  • To gather recommendations from stakeholders on improving pediatric TB treatment accessibility.
  • To address formulation, supply chain, and regulatory barriers in pediatric TB pharmacotherapy.

Main Methods:

  • Consultation with representative stakeholders involved in pediatric TB drug access.
  • Analysis of stakeholder feedback to identify critical areas for improvement.
  • Synthesis of recommendations for policy and practice.

Main Results:

  • Development of child-friendly, adequately dosed drug formulations with extended shelf life is essential.
  • Streamlined regulatory approvals and incentivization of manufacturers are needed.
  • Enhanced coordination among stakeholders, improved diagnosis, and pooled procurement are vital for market supply and affordability.

Conclusions:

  • A multi-faceted approach is required to improve pediatric TB drug access.
  • Investment in new formulations, regulatory efficiency, and supply chain management is critical.
  • Collaborative efforts and incentivized manufacturing will ensure sustained availability of affordable pediatric TB treatments.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
864
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
704
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
699